Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria

PAUL NEWTON,1,2 YUPIN SUPUTTAMONGKOL,3 PAKTIYA TEJA-ISAVADHARM,4 SASITHON PUKKITTAYAKAMEE,1 V NAVARATNAM,5 IMELDA BATES,6 AND NICHOLAS WHITE1,2,1*

Faculty of Tropical Medicine, Mahidol University, 1Department of Medicine, Siriraj Hospital, 3 and Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, 4 Bangkok, Thailand; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, 2 and Liverpool School of Tropical Medicine, Liverpool,6 United Kingdom; and National Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia5

Received 8 March 1999/Returned for modification 25 August 1999/Accepted 8 January 2000

The pharmacokinetic properties of oral and intravenous artesunate (2 mg/kg of body weight) were studied in 19 adult patients with acute uncomplicated Plasmodium falciparum malaria by using a randomized crossover design. A sensitive bioassay was used to measure the antimalarial activity in plasma which results from artesunate and its principal metabolite, dihydroartemisinin. The oral study was repeated with 15 patients during convalescence. The mean absolute oral bioavailability of the antimalarial agent in patients with acute malaria was 61% (95% confidence interval [CI], 52 to 70%). The absorption and elimination of oral artesunate were rapid, with a mean elimination half-life of antimalarial activity of 43 min (95% CI, 33 to 53 min).

Optimization of dosing recommendations is also important because of evidence that high doses of parenteral artesunate are neurotoxic in experimental mammals (16). Oral artesunate and artemether, but not artemisinin, are hydrolyzed rapidly back to the common metabolite DHA, which is intrinsically more active as an antimalarial agent. Oral artesunate may be considered mainly a prodrug for DHA, as the metabolite is the main contributor to overall antimalarial activity (2, 6). Thus, in order to compare different formulations of these drugs accurately and to guide the accurate choice of compound, the bioavailability of the antimalarial agent must be assessed.

Chemical methods for the assay of DHA and the related derivatives have a limit of accurate quantitation above the range of concentrations which provide significant antimalarial effect. High-performance liquid chromatography (HPLC) with electrochemical detection (ECD) (14) is considered the “gold standard,” but this method is difficult, time-consuming, and expensive. HPLC methods with UV detection and pre- or postcolumn derivatization are simpler but have limits of detection some 10 times higher than the 50% inhibitory concentrations (IC50s) for antimalarial activity. Bioassay gives an alternative and considerably more sensitive measure and provides important clinical pharmacodynamic information. However, it does not distinguish between parent drugs and their active metabolites (20). We have used the sensitive bioassay, supplemented by HPLC-ECD, to assess the bioavailability and disposition of oral artesunate during acute uncomplicated falciparum malaria and during convalescence.

MATERIALS AND METHODS

Patients. This study was conducted in Paholpolpayahasena Hospital, Kanchanaburi, western Thailand, in 1993. Nonpregnant adults (age, >14 years) hospitalized with uncomplicated acute P. falciparum malaria (26) were included in the study, provided that they gave fully informed consent and had not received previous treatment with an artesinin derivative. Pretreatment with quinine was checked by a urine dipstick screening method (19). The study was approved by the ethical and scientific review subcommittee of the Royal Thai Government Ministry of Public Health.

Clinical procedures. On admission the patients were weighed; a full clinical examination was conducted; and venous hematocrit, urea and electrolytes, creatinine, liver enzymes, glucose, and lactate levels were measured. Samples for thick and thin blood smears were taken, and quantitative parasite counts were recorded.

Drug and sampling regimens. Patients were initially randomized to receive either oral or intravenous artesunate at a dose of 2 mg/kg of body weight. The parenteral drug was dispensed as artesunic acid powder at 60 mg per ampoule (Guilin No. 2 Factory, Guangxi, People’s Republic of China) and was dissolved in 1 ml of 5% sodium bicarbonate (to form sodium artesunate) and was then diluted to 5 ml in 5% dextrose and given by intravenous bolus injection. The 50-mg artesunate tablets (Guilin No. 1 Factory; Guangxi, People’s Republic of China) were crushed, dissolved in water to provide the weight-adjusted dose (within ±2.5 mg), and immediately given to the patient. Blood samples were...
taken through an indwelling catheter in a forearm vein at 0, 1, 5, 15, 30, 45, 60, 90, and 120 min and then at 3, 4, 6, 8, 12, 18, and 24 h following drug administration. A second dose of artesunate (2 mg/kg) was then given by the opposite route, i.e., if oral administration was given first, then intravenous administration was given second. Blood samples were again taken at the same time intervals at which they were taken on the first day. On day 3, mefloquine (25 mg/kg; Lariam; Roche) was given to complete the treatment. Vital signs were recorded every 4 h, and hematocrit and parasitemia levels were measured every 6 h until parasite clearance (defined as the first negative thick film, i.e., no parasites seen, after the counting of 200 white blood cells). Following recovery and discharge from hospital, the patients were asked to return for a convalescent-phase study. The hematocrit and parasitemia levels were checked, and, provided the patient was fully recovered and blood smear negative for malaria parasites, the same oral artesunate dose (2 mg/kg) was readministered, followed by the same regimen of blood sampling described above.

**Drug assays.** Immediately after they were taken, the blood samples were centrifuged and the plasma was stored at −80°C for up to 1 month and then at −20°C for ≤48 months until assay. Antimalarial activity in plasma was measured, as described previously, with an in vitro bioassay for P. falciparum. The area under the curve (AUC) from 0 to 24 h was calculated by using the linear trapezoidal rule. Clearance (CL) was calculated from the model-independent equation CL = dosei.v.)/(AUC0–24i.v.) (where i.v. is intravenous). The area under the curve (AUC) from 0 to 24 h for these potential confounders by calibrating the baseline concentrations in serum (mean, 1,021 ng/ml) after acute-phase oral administration of the drug was estimated not to have changed. The same approach accommodates the antimalarial action of mefloquine (half-life, 2 to 3 weeks [23]) in the convalescent-phase study samples. The only oral drugs taken by the patients immediately before or during the study were acetaminophen (paracetamol; 800 mg, 4 h), mebendazole (400 mg, 1 h), metoclopramide (10 mg, 1 h), and folic acid (2.5 mg, 2 h), respectively. An open one-compartment model with first-order kinetics gave a good fit for 17 of the data points (n = 5). None of these drugs are known to interact with artesunate.

### RESULTS

**Clinical responses.** Twenty adult patients (17 males and 3 females) hospitalized with uncomplicated falciparum malaria were enrolled in the study. One patient was excluded from the subsequent analysis because insufficient clinical data were recorded. At the time of presentation the patients had been ill for a median of 3 days (range, 1 to 10 days) with fever, headache, anorexia, nausea, and vomiting. The clinical and laboratory findings upon admission are shown in Table 1. The median parasite clearance time was 32 h (range, 8 to 88 h). All patients made a rapid and uncomplicated recovery. There were no significant differences in clinical or laboratory features between those patients who received oral or intravenous artesunate first (P > 0.04 for all comparisons). Two patients vomited after administration of the oral dose during the acute phase, at 3 and 0.75 h, respectively, after their individual maximum concentrations in serum (Cmax) had been reached. Fifteen patients returned for the convalescent-phase oral dose study a median of 7 days (range 5 to 31 days) after initial admission. No patient had malaria parasites on thick films at follow-up. The characteristics of the 15 patients who returned for follow-up did not differ from those of the 19 patients studied during the acute phase (P > 0.05). No adverse effects of the study drug were noted.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>27</td>
<td>18–41</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td>53</td>
<td>41–64</td>
</tr>
<tr>
<td>Temp (°C)</td>
<td>38.3</td>
<td>36.5–41.0</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>38</td>
<td>21–44</td>
</tr>
<tr>
<td>Parasite count (no./μl)^a</td>
<td>24,285</td>
<td>832–185,888</td>
</tr>
<tr>
<td>Total serum bilirubin concn (μmol/liter)^c</td>
<td>21.1</td>
<td>6.8–48.2</td>
</tr>
<tr>
<td>Serum creatinine concn (μmol/liter)^b</td>
<td>115</td>
<td>97–141</td>
</tr>
<tr>
<td>Plasma lactate concn (mmol/liter)^f</td>
<td>2.7</td>
<td>1.3–4.4</td>
</tr>
<tr>
<td>Serum albumin concn (g/liter)^b</td>
<td>33</td>
<td>24–39</td>
</tr>
</tbody>
</table>

^a Counts are (number of asexual parasites/1,000 erythrocytes on thin film × percent hematocrit × 125.6) or (number of asexual parasites/200 white blood cells on thick film × 40), assuming that the peripheral white blood cell count is 8 × 10^9/liter.

^b Geometric mean.

^c Normal range, 3 to 17 μmol/liter.

^d Normal range, 70 to 150 μmol/liter.

^e Normal range, <4 mmol/liter.

^f Normal range, 35 to 50 g/liter.

### Drug measurements.** Three patients were found to have received quinine, one patient was found to have received chloroquine, and one patient was found to have received tetrazycline before the study. The bioassay method was able to control for these potential confounders by calibrating the baseline plasma sample as having zero DHA equivalents. In these cases the considerably lower levels of antimalarial activity from quinine, chloroquine, and tetracycline (half-lives, 16 to 18 h, 30 to 60 days, and 8 h, respectively [21, 23]) or (number of asexual parasites/200 white blood cells on thick film × percent hematocrit × 125.6) or (number of asexual parasites/200 white blood cells on thick film × 40), assuming that the peripheral white blood cell count is 8 × 10^9/liter.

#### Pharmacokinetic and statistical analysis

### Petri dish bioassay with intravenous administration and HPLC with in-vitro bioassay for P. falciparum. The considerably lower levels of antimalarial activity from quinine, chloroquine, and tetracycline (half-lives, 16 to 18 h, 30 to 60 days, and 8 h, respectively [21, 23]) or (number of asexual parasites/200 white blood cells on thick film × percent hematocrit × 125.6) or (number of asexual parasites/200 white blood cells on thick film × 40), assuming that the peripheral white blood cell count is 8 × 10^9/liter.

#### Pharmacokinetic and statistical analysis

### Open one- and two-compartment models were fitted to the plasma concentration-time data, and standard pharmacokinetic parameters were derived. Curve fitting was performed with WinNonlin (User’s guide for WinNonlin; Scientific Consulting, Inc., Cary, N.C.), which is a weighted, iterative, nonlinear regression procedure. Compartmental models were chosen on the basis of the Akaike Information Criterion (AIC) and standard pharmacokinetic equations applied (User’s guide for WinNonlin; Scientific Consulting, Inc., Cary, N.C.). The area under the curve (AUC) from 0 to 24 h (AUC0–24) was calculated by using the linear trapezoidal rule. Clearance (CL) was calculated from the model-independent equation CL = dosei.v.)/(AUC0–24i.v.) (where i.v. is intravenous administration), and the area under the curve (AUC) from 0 to 24 h was estimated not to have changed. The same approach accommodates the antimalarial action of mefloquine (half-life, 2 to 3 weeks [23]) in the convalescent-phase study samples. The only oral drugs taken by the patients immediately before or during the study were acetaminophen (paracetamol; 800 mg, 4 h), mebendazole (400 mg, 1 h), metoclopramide (10 mg, 1 h), and folic acid (2.5 mg, 2 h), respectively. An open one-compartment model with first-order kinetics gave a good fit for 17 of the data points (n = 5). None of these drugs are known to interact with artesunate.

#### Pharmacokinetics. (i) Models. An open two-compartment model with first-order kinetics gave a good fit for 17 of the data sets for bioassay with intravenous administration, with a mean AIC of 147 (95% confidence interval [CI], 137 to 157) (Fig. 1; Table 2). Fitting of the one-compartment models to these data sets gave significantly higher mean AIC values (190 [95% CI, 182 to 198]; P < 0.0001). The two remaining data sets, for bioassay with intravenous administration and HPLC with intravenous administration, could be modeled only with a one-compartment model, with AIC values of ≤160 and ≤205, respectively. An open one-compartment model with first-order absorption and elimination provided a good fit to the plasma concentration-time data sets for bioassay following oral administration (Table 3) and the acute-phase oral and convalescent-phase data sets for the HPLC assay (median AIC, 143; range, 86 to 180). No significant differences were found between the pharmacokinetic parameters if artesunate was given intravenously first or second (P > 0.05 for all comparisons).

#### (ii) Absorption. Oral artesunate was absorbed rapidly, reaching peak antimalarial concentrations in a median of 0.75 h (range 0.5 to 4.0 h) and 1.00 h (range, 0.5 to 4.00 h) for acute- and convalescent-phase oral doses, respectively (P = 0.9). Cmax ranged between 268 and 2,506 ng of DHA equivalents per ml (mean, 1,021 ng/ml) after acute-phase oral ad-
ministration but ranged between 137 and 1,040 ng/ml (mean, 546 ng/ml) after administration during the convalescent phase (Table 3). Antimalarial activity 5 min after intravenous injection in patients with acute malaria was considerably higher, ranging between 2,809 and 9,757 ng/ml (median, 5,100 ng/ml) (Fig. 1 and 2; Tables 2 and 3). The calculated mean absolute antimalarial bioavailability of the acute oral dose was 61% (95% CI, 52 to 70%; range, 30 to 104%).

(iii) Disposition. The mean elimination half-lives of antimalarial activity were 44 min (95% CI, 38 to 50 min), 43 min (95% CI, 33 to 53 min) and 50 min (95% CI, 35 to 65 min) for intravenous, acute-phase oral, and convalescent-phase oral administrations, respectively ($P > 0.2$ for all comparisons).

After intravenous, acute-phase oral, and convalescent-phase oral administrations for one, two, and three patients, respectively, the antimalarial activity had not reached zero 24 h after dosing. Assuming ~70% in vivo drug protein binding (11), the residual low concentrations (median, 4.0 ng of DHA equivalents per ml [range, 1 to 25 ng/ml]) are just below the current range of in vitro IC$_{50}$ of DHA for *P. falciparum* in western Thailand (A. Brockman, personal communication). Among the remaining patients the earliest time at which no antimalarial activity was detected was a median of 8 h (range, 6 to 24 h) for intravenous administration, 8 h (range, 6 to 18 h) for acute-phase oral administration, and 8 h (range, 3 to 14 h) for convalescent-phase oral administration.

The estimated CL of antimalarial activity following acute-phase oral artesunate administration was positively correlated with that following acute-phase intravenous administration ($r = 0.66; P = 0.003$) but not with that following convalescent-phase oral artesunate administration ($P = 0.8$). There were no significant relationships between any of the derived pharmacokinetic variables and clinical and laboratory measurements upon admission ($P > 0.05$).

Acute-phase oral administration gave peak antimalarial activities and AUC$_{10-24}$ values which were approximately twice as high as those during the convalescent phase and, thus, corresponding lower estimates for apparent volume of distribution and CL that were approximately half those during the convalescent phase and, thus, corresponding lower estimates for apparent volume of distribution and CL that were approximately half those during the convalescent phase (Table 3). The convalescent-phase AUC$_{10-24}$ was a mean of 61% (95% CI, 40 to 82%) of the acute-phase AUC$_{0-24}$ after oral administration. The ratios of convalescent-phase oral AUC$_{0-24}$/acute-phase AUC$_{0-24}$ after oral adminis-
tration did not correlate significantly with any clinical or laboratory measurements ($P > 0.05$). There were no significant differences between acute-phase and convalescent-phase oral treatment regimens in times to $C_{\text{max}}$ absorption rate constants, and lag times ($P > 0.19$).

(iv) HPLC data. The HPLC assays for artesunate and DHA for three patients yielded 12 data sets (Table 4). Although the sample size is small, the data suggest that artesunate is rapidly and largely converted to DHA (Fig. 2). For the three patients the AUC$_{0-24}$ for DHA after oral administration during the acute phase as a percentage of the AUC$_{0-24}$ determined by the antimalarial bioassay were 72, 95, and 102%, respectively. For each of these patients the time to $C_{\text{max}}$ after drug administration was longer for DHA than for artesunate.

**DISCUSSION**

Oral artesunate is a widely used, very well tolerated, and highly effective antimalarial agent. Its rapid and consistent activity against multidrug-resistant strains of *P. falciparum* has led to its increasing use in areas such as southeast Asia where there is widespread resistance to other antimalarial drugs (8, 15). Other members of this class, artemisinin, artemether, arteether, and dihydroartemisinin, are also in clinical use. There are several different pharmaceutical formulations of each drug, and they may have significantly different pharmacokinetic properties (13). The present pharmacokinetic data on the original Chinese oral artesunate formulation, which is by far the most widely used formulation and which has been used in most...
of the clinical trials of artesunate, provide a benchmark against which other formulations and derivatives may be compared. Comparison of bioactivity and HPLC results suggests that oral artesunate is largely converted to the more active antimalarial metabolite DHA, as has been documented for oral artemether (20). Oral artesunate is absorbed rapidly, with absolute bioavailability averaging 61%, although there is considerable interpatient variation. The coefficient of variation of the antimalarial activity AUC following oral administration was similar in patients with acute malaria (42%) and in patients in the convalescence phase (34%) (Table 3), which indicates that much of the interindividual variation is due to patient factors and not variation in disease severity. The absolute bioavailability of artesunate cannot be compared with those of other artemisinin derivatives as there are no intravenous formulations of these other drugs.

The absolute antimalarial bioavailability of artesunate found in this study is lower than the DHA bioavailability reported recently for Vietnamese adults with uncomplicated falciparum malaria (mean, 82%; 95% CI, 71 to 92%) and vivax malaria (mean, 85%; 95% CI, 68 to 101%) as determined by a less sensitive but reliable HPLC assay with UV detection (3, 4). The bioavailability reported here represents total antimalarial activity, whereas the estimates of Batty et al. (3, 4) represent only the bioavailability of DHA. Assuming that artesunate is entirely converted to DHA, the sum of published AUCs for artesunate and DHA after intravenous and oral administration (3, 4), corrected for their molecular weights, can be used to estimate the corresponding total antimalarial bioavailability. This yields antimalarial bioavailability estimates of 56 and 71% for falciparum and vivax malaria patients, respectively, consistent with the results presented here. The derived pharmacokinetic parameters were also similar in both studies. Four factors may confound comparisons between pharmacokinetic studies of artesunate. First, the calculation of the AUC₀–₂₄ after intravenous administration is highly dependent on the extrapolated concentration at time zero, and therefore, errors in the concentration at time zero will have a profound effect on the calculated bioavailability. Indeed, the AUC for the first 15 min after dosing is nearly half (mean, 42%; 95% CI, 37 to 47%) of the total AUC in the first 24 h. Second, disease severity may vary and the patients recruited into this study may have had more severe disease than those described earlier (4), with higher levels of parasitemia and higher serum creatinine and bilirubin concentrations. Third, the study drugs may have different contents. Batty et al. (3, 4) found that 50-mg artesunate tablets (which were from the same source as those used in this study) had a mean artesunate concentration of 44.8 mg (95% CI, 42.8 to 46.7 mg). If this correction is applied to our data, the estimated mean absolute bioavailability of oral artesunate was 68% (95% CI, 58 to 78%). Fourth, different assay methods may give different results.

Vietnamese children who had moderately severe malaria and who were given 3 mg of oral artesunate per kg had lower mean Cmax (664 ng of DHA equivalents per ml) and AUC (1,286 ng·h/ml) values, as determined by the same bioassay, compared with those achieved in the present study. Children may have higher levels of drug clearance than adults (6).

The significantly lower AUC₀–₂₄ during the convalescent phase probably did not result from a reduction in absolute oral bioavailability per se; indeed, the opposite would have been more likely as visceral blood flow and intestinal absorption are reduced in patients with acute malaria and should have returned to normal during the convalescent phase (12, 17). The reduction in AUC probably results from expansion in the apparent volume of distribution and improved systemic clearance on recovery with increased pre-systemic (first-pass), intestinal, and hepatic metabolism. In patients with acute malaria the apparent volume of distribution of protein-bound basic drugs, such as quinine and presumably the artemisinin derivatives, is reduced as a consequence of increased binding to α1-acid glycoprotein (11, 18). It is not clear whether hepatic artesunate and DHA metabolism is autoinduced, as has been described for artemisinin itself (1, 9). This study cannot distinguish between the pharmacokinetic effects of disease and autoinduction.

Artesunate is readily hydrolyzed to DHA, probably by blood esterases and the hepatic cytochrome P450 3A₄, as is the case with the closely related compounds artesunic acid and arteether (7, 25). Artemether is also probably biotransformed by intestinal cytochrome P450 3A₄ (M. A. van Agtmael, V. Gupta, and C. J. van Boxtel, Abstr. 38th Intersci. Conf. Antimicrob Agents Chemother., abstr. A-081, p. 26, 1998). If artesunate is similarly metabolized, interindividual variability in intestinal P450 3A₄ activity may be important in determining bioavailability. Comparison of bioassay and HPLC results suggests that the majority of antimalarial activity can be explained by DHA, which is cleared predominantly by hepatic biotransformation either to biologically inert glucuronides (such as DHA-glucuronide (with the glucuronide at the 12 position) or to metabolites which lack the peroxide bridge necessary for antimalarial activity (5, 7, 10, 11; K. Ilett, T. M. E. Davis, K. T. Batt, J. L. Newton et al.).

### Table 4. Summary of results of HPLC assays for artesunate and DHA

<table>
<thead>
<tr>
<th>Variable</th>
<th>Oral administration</th>
<th>Convalescent phase</th>
<th>Intravenous administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Artesunate¹</td>
<td>DHA²</td>
<td>Artesunate</td>
</tr>
<tr>
<td>No. of patients</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>AUC₀–₂₄ (ng·h/ml)</td>
<td>210 (70–667)</td>
<td>1,334 (1,018–2,673)</td>
<td>317</td>
</tr>
<tr>
<td>k₁₀⁻¹ (h⁻¹)</td>
<td>10.50 (2.55–47.91)</td>
<td>9.47 (2.36–9.69)</td>
<td>0.618</td>
</tr>
<tr>
<td>t₀¹₀ (h)</td>
<td>1.29 (1.05–1.97)</td>
<td>1.06 (1.02–1.46)</td>
<td>0.623</td>
</tr>
<tr>
<td>tₚ₀ (h)</td>
<td>0.54 (0.35–0.66)</td>
<td>0.65 (0.47–0.68)</td>
<td>1.11</td>
</tr>
<tr>
<td>tₘ₀ (h)</td>
<td>0.19 (0.00–0.25)</td>
<td>0.22 (0.14–0.45)</td>
<td>0.27</td>
</tr>
<tr>
<td>tₘ₁ (h)</td>
<td>0.50 (0.25–0.50)</td>
<td>0.75 (0.5–1.0)</td>
<td>3</td>
</tr>
<tr>
<td>tₘ₂ (h)</td>
<td>0.50 (0.25–0.50)</td>
<td>0.75 (0.5–1.0)</td>
<td>1</td>
</tr>
<tr>
<td>Cmax (ng/ml)³</td>
<td>198 (61–510)</td>
<td>1,052 (817–2,853)</td>
<td>98</td>
</tr>
<tr>
<td>V (liters/kg)</td>
<td>7.1 (1.8–31.4)</td>
<td>1.49 (0.68–1.69)</td>
<td>8.75</td>
</tr>
<tr>
<td>CL (liters/kg·h)</td>
<td>9.51 (2.99–32.80)</td>
<td>1.50 (0.75–2.24)</td>
<td>6.32</td>
</tr>
</tbody>
</table>

¹ Values are medians (ranges). Abbreviations are as defined in footnotes a and b.
² To convert artesunate in nanograms per milliliter to nanomoles per liter, multiply by 2.601.
³ To convert DHA in nanograms per milliliter to nanomoles per liter, multiply by 3.517.

a Cmax is the observed value for the oral administration data sets and the extrapolated value for the intravenous administration data sets.

Following artesunate administration, antimalarial activity was eliminated rapidly, with terminal half-lives of approximately 45 min. Despite this, once-daily administration to patients with acute malaria has proved highly effective and gives parasite and fever clearance times equivalent to those achieved with twice-daily administration (15). Transient exposure to parasitidal concentrations of the drug twice per parasite asexual life cycle are sufficient for an optimum pharmacodynamic effect. However, the considerable interindividual variability in the profile of the concentration of the drug in blood argues in favor of using a dose higher than 2 mg/kg, at least initially, for the treatment of acute uncomplicated falciparum malaria.

ACKNOWLEDGMENTS

We are very grateful to the director and staff of Paholpolpayuhasena Hospital and to Duangsuda Keeratithakul, Maneerat Rasameesoraj, Richard Newton, Kamolrat Silamut, and Julie Simpson for help. Alan Brockman kindly provided the IC50 data.

The bioassay was supported by the U.S. Army Medical Component, Armed Forces Research Institute of Medical Science, Bangkok, Thailand, and the U.S. Army Medical Research and Materiel Command, Fort Detrick, Frederick, Md., and the HPLC assay was supported by the Tropical Diseases Research Programme of the World Health Organization. This study was part of the Wellcome Mahidol University Oxford Tropical Medicine Research Programme funded by The Wellcome Trust of Great Britain.

REFERENCES